Stockscreener 앱 받기
1.95
5.41%
0.10
시간 외 거래:
1.86
-0.09
-4.62%
Bluejay Diagnostics Inc 주식(BJDX)의 최신 뉴스
BJDX SEC FilingsBluejay Diagnostics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Bluejay Diagnostics, Inc. Enters Securities Purchase Agreement for $25,000 Private Placement of Common Stock - Minichart
Bluejay Diagnostics Announces Insider-Funded Private Stock Placement - TipRanks
Bluejay Diagnostics completes $125,000 private placement with board members - Investing.com
Bluejay Diagnostics Raises $125,000 in Insider Private Placement at $2.00 Per Share - TradingView
Bluejay Diagnostics (NASDAQ: BJDX) insiders purchase $125K in private stock deal - Stock Titan
Fed Meeting: Is Bluejay Diagnostics Inc gaining market shareEntry Point & Weekly Return Optimization Alerts - baoquankhu1.vn
Bluejay Diagnostics, Inc. announced that it has received $0.125 million in funding - marketscreener.com
Bluejay Diagnostics Evaluates Potential Acquisition Opportunity While Prioritizing Core Critical Care Platform Initiatives - Minichart
Bluejay Diagnostics sends response letter to NorthStrive Fund II LP - Investing.com
Bluejay Weighs Proposed Therapeutic Acquisition, Reaffirms Symphony Focus - TipRanks
Bluejay Diagnostics sends response letter to NorthStrive Fund II LP By Investing.com - Investing.com UK
Bluejay responds to investor on possible therapeutic acquisition while prioritizing Symphony platform execution - TradingView
Bluejay Diagnostics (BJDX) reviews NorthStrive proposal for cough therapy acquisition - Stock Titan
Buyout Rumor: What is Bluejay Diagnostics Incs book value per shareTrade Exit Summary & Real-Time Volume Analysis - baoquankhu1.vn
Bluejay Diagnostics, Inc. announced that it expects to receive $0.125 million in funding - marketscreener.com
Bluejay Advances Symphony IL-6 Sepsis Diagnostic Program - TipRanks
Bluejay Diagnostics: SYMON-I IL-6 Findings Accepted for SAEM 2026 Presentation - TradingView
Bluejay Diagnostics (NASDAQ: BJDX) highlights SYMON-I IL-6 sepsis data at 2026 SAEM - Stock Titan
Bluejay Diagnostics to Present Findings on IL-6 as a Biomarker for Sepsis at 2026 SAEM Annual Meeting - Quiver Quantitative
Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting - The Manila Times
Study explores link between ER inflammation marker and organ damage in sepsis - Stock Titan
Northstrive Fund II has sent a letter to the Board of Directors of Bluejay Diagnostics Inc, recommending that they carefully evaluate a potential acquisition opportunity. - Bitget
NorthStrive Fund II LP Issues Open Letter to the Board and Shareholders of Bluejay Diagnostics - The Manila Times
Braeden Lichti Pushes for Changes at Bluejay Diagnostics with 3.65% Stake - TradingView
Activist investor presses deal at Bluejay Diagnostics (NASDAQ: BJDX) - Stock Titan
Activist investor files 13D in Bluejay Diagnostics (BJDX), pushes biotech acquisition review - Stock Titan
Investor presses Bluejay Diagnostics (NASDAQ: BJDX) on biotech acquisition idea - Stock Titan
Bluejay Diagnostics Provides Corporate Update and 2026 Strategic Outlook - marketscreener.com
Aug Opening: Is Bluejay Diagnostics Inc a good ESG investmentMarket Sentiment Report & Technical Pattern Based Buy Signals - baoquankhu1.vn
Bluejay 10-K: Net loss $6.85M, operating loss $6.95M; cash through Q3 2026 - TradingView
Medical diagnostics company Bluejay Diagnostics Inc (stock code: BJDX) is facing financial pressure. According to the company's latest disclosed financial plan, in order to maintain normal operations and advance R&D projects, it must secure at least $20 milli - Bitget
Bluejay Diagnostics says SYMON II study ‘progressing as planned’ - TipRanks
Bluejay’s 20-minute sepsis test drives 2026 plan and $20M cash goal - Stock Titan
Bluejay Diagnostics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
BJDX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
BJDX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
BJDX Should I Buy - Intellectia AI
ARMISTICE CAPITAL, LLC Acquires Shares in Bluejay Diagnostics Inc - GuruFocus
BJDXBluejay Diagnostics Inc Latest Stock News & Market Updates - Stock Titan
Why is Bluejay Diagnostics Inc. stock going downWeekly Trade Summary & Reliable Momentum Entry Alerts - mfd.ru
Bluejay Diagnostics Completes Warrant Exercises, Clarifies Capital Structure - TipRanks
Bluejay Diagnostics says all prefunded warrants exercised; ~972,000 shares outstanding, 1.5M cash-exercise warrants - TradingView
Bluejay Diagnostics’ Clinical Study Marks Key Transition from Enrollment to Data Analysis - StocksToTrade
Prefunded warrants fully exercised at Bluejay Diagnostics (NASDAQ: BJDX) - Stock Titan
Bluejay Diagnostics completes prefunded warrant exercises By Investing.com - Investing.com Canada
Bluejay Diagnostics Announces Full Exercise of Prefunded Warrants and Current Share Structure Update - Quiver Quantitative
Bluejay Diagnostics Announces All Prefunded Warrants Now Exercised - marketscreener.com
Medical diagnostics firm ends prefunded warrants, flags 13G share confusion - Stock Titan
Why Etsy Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket - Benzinga
Bluejay Advances SYMON II Sepsis Study and Manufacturing - TipRanks
Bluejay Diagnostics enrolls 545 patients in SYMON II study - TipRanks
Bluejay Diagnostics successfully enrolls 545 patients in Symon(TM) II study and advances manufacturing readiness into 2026 - marketscreener.com
Bluejay Diagnostics Successfully Enrolls 545 Patients in SYMON™ II Study and Advances Manufacturing Readiness into 2026 - The Manila Times
Bluejay Diagnostics Successfully Enrolls 545 Patients in SYMON II Study and Advances Manufacturing Readiness into 2026 - Bitget
Bluejay Diagnostics Successfully Enrolls 545 Patients In Symon™ Ii Study And Advances Manufacturing Readiness Into 2026 - TradingView
Bluejay Diagnostics, Inc. Successfully Enrolls 545 Patients in SYMON?? II Study and Advances Manufacturing Readiness into 2026 - marketscreener.com
Is Bluejay Diagnostics Inc. stock a smart retirement pickTrade Exit Summary & Entry Point Confirmation Signals - mfd.ru
Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Sees Large Increase in Short Interest - Defense World
0.85%
1.86%
자본화:
|
볼륨(24시간):